Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL news (Ticker: AVR), a resource for investors and traders seeking the latest updates and insights on ANTERIS TECHNOLOGIES GLOBAL stock.
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) generates news primarily around its structural heart programs, clinical data and capital markets activities. As a company focused on medical instruments and supplies for structural heart disease, its announcements center on the development of the DurAVR Transcatheter Heart Valve (THV) System and related regulatory and trial milestones.
Investors following AVR news will see regular updates on clinical outcomes for DurAVR THV in patients with severe aortic stenosis, including small aortic annulus cohorts. Recent releases have detailed 30‑day and one‑year results from pooled analyses of patients treated in the EMBARK Study and early feasibility studies in the United States and Europe, highlighting hemodynamic performance, effective orifice areas, paravalvular leak rates, valve‑related mortality and prosthesis‑patient mismatch metrics.
News coverage also tracks the progress of the PARADIGM Trial, Anteris’ global prospective randomized controlled trial comparing DurAVR THV with commercially available TAVR devices. Key items include first European regulatory clearance from the Danish Medicines Agency, first patients enrolled and treated in Denmark, and U.S. FDA approval of the Investigational Device Exemption to initiate the trial, with recruitment in the United States subject to Institutional Review Board approval.
Beyond clinical data, Anteris issues updates on quarterly financial results, cash flows and operating expenditure linked to regulatory work, trial preparation and manufacturing scale‑up for DurAVR THV. Additional news items cover capital raising transactions involving common stock, CHESS Depositary Interests and warrants, as well as corporate governance events such as special meetings and the annual meeting of stockholders.
For readers tracking AVR, this news stream offers insight into the pace of clinical development, regulatory interactions, trial execution and financing activities that shape the company’s structural heart strategy.
Anteris Technologies (NASDAQ: AVR) presented 30-day pooled outcomes for 100 small‑annulus severe aortic stenosis patients treated with the DurAVR® THV at PCR London Valves (Nov 17, 2025).
Key results: mean pressure gradient 8.2 ± 3.1 mmHg, effective orifice area 2.2 ± 0.3 cm2, 0 valve‑related deaths, 0 moderate/severe paravalvular leak, and 97% freedom from moderate/severe prosthesis‑patient mismatch; technical success was 100% in the last 50 consecutive implants. The analysis pools EMBARK and early feasibility studies and represents ~20% of planned PARADIGM randomized cohort enrollment.
Anteris (NASDAQ: AVR) reported Q3 2025 results and a corporate update focused on advancing the PARADIGM pivotal trial and scaling manufacturing. Key regulatory milestones included FDA approval to commence U.S. recruitment announced in November 2025 and Danish Medicines Agency approval with the first PARADIGM patients treated in Denmark in October 2025. The company progressed site readiness across the U.S., Europe and Canada, advanced QMS and ISO 13485 preparation, and continued manufacturing scale-up for DurAVR THV production.
Financial highlights: net operating cash outflows $59.3M for the nine months ended Sept 30, 2025; R&D $16.8M and SG&A $5.8M for Q3; cash and cash equivalents of $9.1M at Sept 30, 2025.
Anteris (NASDAQ:AVR) announced that the U.S. Food and Drug Administration granted approval to initiate the PARADIGM global Investigational Device Exemption (IDE) clinical trial for the DurAVR® Transcatheter Heart Valve (THV) on November 3, 2025. The randomized pivotal trial will compare the DurAVR biomimetic valve to commercial TAVR devices in patients with severe calcific aortic stenosis and is intended to support a future PMA submission.
The company said U.S. patient recruitment can now begin, and noted the trial recently launched with first patients treated in Denmark. The study is co-chaired by Dr. Michael J. Reardon and Professor Stephan Windecker.
Anteris (NASDAQ: AVR) reported one-year pooled outcomes for the DurAVR® Transcatheter Heart Valve (THV) in patients with small aortic annuli (mean annulus area 396 ± 37 mm2).
Key results: EOA 2.1 ± 0.2 cm2, mean pressure gradient 8.6 ± 2.6 mmHg, no valve-related mortality and no moderate or severe paravalvular leak at one year; 30-day prosthesis-patient mismatch was 1.5% versus 11.2%–35.3% for current devices. The pooled cohort included 65 small-annulus patients from EMBARK and a US early feasibility study; >100 patients have been implanted overall. Results will be evaluated further in the randomized PARADIGM pivotal trial (NCT07194265).
Anteris Technologies (NASDAQ: AVR) announced on October 27, 2025 that the first patients were enrolled and successfully treated in the global pivotal PARADIGM Trial evaluating the DurAVR® Transcatheter Heart Valve (THV) for severe calcific aortic stenosis.
The initial procedures were performed at Rigshospitalet, Copenhagen by Prof. Dr. Ole De Backer. The head-to-head study will randomize patients across surgical risk groups and builds on an existing clinical dataset of 130 patients previously treated with DurAVR® (including de novo, valve-in-valve, and bicuspid anatomies). Anteris plans near-term expansion of PARADIGM into the United States, Europe and Canada to accelerate enrollment and evidence generation toward commercialization.
Anteris Technologies (NASDAQ: AVR) announced that one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) will be presented at TCT 2025 on October 27, 2025 at 2:27pm GMT-7 in the Innovation Theater, Moscone Center, San Francisco.
The oral presentation, titled “The DurAVR® Biomimetic TAVR System in Patients with Small Aortic Annuli (Anteris): One-Year Clinical and Hemodynamic Outcomes,” summarizes outcomes in over 100 patients with symptomatic severe aortic stenosis and small aortic annuli (annulus area 396 ± 37 mm2). The company said the outcomes to date are encouraging and will be further evaluated in the global pivotal PARADIGM Trial, a prospective randomized controlled trial comparing DurAVR THV to commercially available TAVRs for safety and effectiveness.
Anteris (NASDAQ: AVR) received regulatory clearance from the Danish Medicines Agency to start the global pivotal PARADIGM Trial of the DurAVR® transcatheter heart valve for severe calcific aortic stenosis, announced on October 15, 2025.
Patient recruitment at Danish centers is expected to begin in 4Q 2025, with planned expansion across the United States, Europe and Canada. An IDE remains under review by the U.S. FDA, and U.S. sites will begin once IDE and IRB approvals are obtained. Management cites trial design aimed to support future PMA and CE Mark approvals.
Anteris Technologies Global Corp. (NASDAQ: AVR) announced the adjournment of its Special Meeting of Stockholders due to lack of required quorum. The meeting has been rescheduled for September 29, 2025, at 8:00 a.m. Central time.
The virtual meeting will be held via webcast, maintaining the original record date of August 11, 2025. Stockholders who haven't voted can still do so, with proxy submissions due by September 28, 2025, at 11:59 p.m. Eastern time for online/telephone votes, and September 26, 2025 for mail-in proxies. CDI holders must submit voting instructions by September 25, 2025, at 5:00 p.m. Central time.
Anteris Technologies Global Corp. (NASDAQ: AVR) has announced the postponement of its Special Meeting of Stockholders from September 11 to September 18, 2025. The virtual meeting will be held at 5:00 p.m. Central time via live webcast.
The postponement aims to provide stockholders additional time to vote on proposals outlined in the Company's August 18 Proxy Statement. The record date remains August 11, 2025. Previously cast votes will remain valid unless changed. The Board unanimously recommends voting FOR the proposals.
Stockholders can vote via Internet or telephone until September 17, while CDI holders must submit their Voting Instruction Forms by September 16. All relevant materials are available on the SEC website and the company's investor relations page.
Anteris Technologies Global Corp. (NASDAQ: AVR) has announced the postponement of its Special Meeting of Stockholders from September 4, 2025, to September 11, 2025, at 5:00 p.m. Central time. The meeting will be held virtually via webcast at www.virtualshareholdermeeting.com/AVR2025SM.
The Record Date remains unchanged at August 11, 2025. The postponement aims to provide stockholders additional time to vote on the proposals outlined in the Company's Proxy Statement filed on August 18, 2025. The Board of Directors unanimously recommends voting FOR all proposals.
Previously cast votes will remain valid unless changed. Stockholders can submit new votes via Internet or telephone by September 10, 2025, while CDI holders must submit voting instructions by September 9, 2025.
FAQ
What is the current stock price of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
What is the market cap of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
